142 related articles for article (PubMed ID: 23111422)
1. Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals.
Lubomirov R; Arab-Alameddine M; Rotger M; Fayet-Mello A; Martinez R; Guidi M; di Iulio J; Cavassini M; Günthard HF; Furrer H; Marzolini C; Bernasconi E; Calmy A; Buclin T; Decosterd LA; Csajka C; Telenti A;
Pharmacogenet Genomics; 2013 Jan; 23(1):9-18. PubMed ID: 23111422
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Concomitant Antiretrovirals and CYP2C9/CYP2C19 Polymorphisms on the Pharmacokinetics of Etravirine.
Green B; Crauwels H; Kakuda TN; Vanveggel S; Brochot A
Clin Pharmacokinet; 2017 May; 56(5):525-536. PubMed ID: 27665573
[TBL] [Abstract][Full Text] [Related]
3. Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals.
Aouri M; Barcelo C; Guidi M; Rotger M; Cavassini M; Hizrel C; Buclin T; Decosterd LA; Csajka C;
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27799217
[TBL] [Abstract][Full Text] [Related]
4. Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients.
Solas C; Simon N; Drogoul MP; Quaranta S; Frixon-Marin V; Bourgarel-Rey V; Brunet C; Gastaut JA; Durand A; Lacarelle B; Poizot-Martin I
Br J Clin Pharmacol; 2007 Sep; 64(3):353-62. PubMed ID: 17517050
[TBL] [Abstract][Full Text] [Related]
5. ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir.
Lubomirov R; di Iulio J; Fayet A; Colombo S; Martinez R; Marzolini C; Furrer H; Vernazza P; Calmy A; Cavassini M; Ledergerber B; Rentsch K; Descombes P; Buclin T; Decosterd LA; Csajka C; Telenti A;
Pharmacogenet Genomics; 2010 Apr; 20(4):217-30. PubMed ID: 20139798
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1.
Yoo HD; Cho HY; Lee YB
Br J Clin Pharmacol; 2010 Jan; 69(1):27-37. PubMed ID: 20078610
[TBL] [Abstract][Full Text] [Related]
7. Population estimation regarding the effects of cytochrome P450 2C19 and 3A5 polymorphisms on zonisamide clearance.
Okada Y; Seo T; Ishitsu T; Wanibuchi A; Hashimoto N; Higa Y; Nakagawa K
Ther Drug Monit; 2008 Aug; 30(4):540-3. PubMed ID: 18641551
[TBL] [Abstract][Full Text] [Related]
8. Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients.
Hirt D; Mentré F; Tran A; Rey E; Auleley S; Salmon D; Duval X; Tréluyer JM;
Br J Clin Pharmacol; 2008 Apr; 65(4):548-57. PubMed ID: 17922881
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous pharmacogenetics-based population pharmacokinetic analysis of darunavir and ritonavir in HIV-infected patients.
Moltó J; Xinarianos G; Miranda C; Pushpakom S; Cedeño S; Clotet B; Owen A; Valle M
Clin Pharmacokinet; 2013 Jul; 52(7):543-53. PubMed ID: 23494984
[TBL] [Abstract][Full Text] [Related]
10. Clinical perspective on antiretroviral drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor etravirine.
Kakuda TN; Schöller-Gyüre M; Hoetelmans RM
Antivir Ther; 2010; 15(6):817-29. PubMed ID: 20834094
[TBL] [Abstract][Full Text] [Related]
11. Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patients.
Kappelhoff BS; Huitema AD; Crommentuyn KM; Mulder JW; Meenhorst PL; van Gorp EC; Mairuhu AT; Beijnen JH
Br J Clin Pharmacol; 2005 Feb; 59(2):174-82. PubMed ID: 15676039
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals.
Arab-Alameddine M; Di Iulio J; Buclin T; Rotger M; Lubomirov R; Cavassini M; Fayet A; Décosterd LA; Eap CB; Biollaz J; Telenti A; Csajka C;
Clin Pharmacol Ther; 2009 May; 85(5):485-94. PubMed ID: 19225447
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial.
Kakuda TN; DeMasi R; van Delft Y; Mohammed P
HIV Med; 2013 Aug; 14(7):421-9. PubMed ID: 23441978
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals.
Arab-Alameddine M; Lubomirov R; Fayet-Mello A; Aouri M; Rotger M; Buclin T; Widmer N; Gatri M; Ledergerber B; Rentsch K; Cavassini M; Panchaud A; Guidi M; Telenti A; Décosterd LA; Csajka C;
J Antimicrob Chemother; 2014 Sep; 69(9):2489-98. PubMed ID: 24821595
[TBL] [Abstract][Full Text] [Related]
15. Interaction between Darunavir and Etravirine Is Partly Mediated by CYP3A5 Polymorphism.
Belkhir L; Elens L; Zech F; Panin N; Vincent A; Yombi JC; Vandercam B; Haufroid V
PLoS One; 2016; 11(10):e0165631. PubMed ID: 27788239
[TBL] [Abstract][Full Text] [Related]
16. Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART.
Bertrand J; Treluyer JM; Panhard X; Tran A; Auleley S; Rey E; Salmon-Céron D; Duval X; Mentré F;
Eur J Clin Pharmacol; 2009 Jul; 65(7):667-78. PubMed ID: 19440701
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Relationships of Etravirine in HIV-1-Infected, Treatment-Experienced Children and Adolescents in PIANO.
Kakuda TN; Brochot A; Green B; Nijs S; Vis P; Opsomer M; Tomaka FL; Hoetelmans RM
J Clin Pharmacol; 2016 Nov; 56(11):1395-1405. PubMed ID: 27060341
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance.
Boffito M; Winston A; Jackson A; Fletcher C; Pozniak A; Nelson M; Moyle G; Tolowinska I; Hoetelmans R; Miralles D; Gazzard B
AIDS; 2007 Jul; 21(11):1449-55. PubMed ID: 17589191
[TBL] [Abstract][Full Text] [Related]
19. Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients.
Elens L; Vandercam B; Yombi JC; Lison D; Wallemacq P; Haufroid V
Pharmacogenomics; 2010 Sep; 11(9):1223-34. PubMed ID: 20860463
[TBL] [Abstract][Full Text] [Related]
20. [Etravirine drug interactions].
Pérez VE; Sánchez-Parra C; Serrano Villar S
Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():27-31. PubMed ID: 20116625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
